Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly has submitted a new drug application to the FDA for Evista for the reduction in risk of breast cancer in postmenopausal women.
Subscribe to our email newsletter
Evista is currently indicated for the treatment and prevention of osteoporosis in postmenopausal women. Evista prevents and treats osteoporosis by helping make bones stronger and less likely to break.
“If approved, Evista would be the only therapy to address two leading health issues for postmenopausal women – osteoporosis and breast cancer,” said Gwen Krivi, vice president of Lilly Research Laboratories. “We believe this potential new indication for Evista would provide a tremendous opportunity for postmenopausal women with these health issues.”
The filing, submitted in November 2006, includes data from four clinical trials.
According to Lilly, the new drug application includes data from more patients than any other submission in the company’s history.